Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy of CAR-T cell therapy in chronic lymphocytic leukemia: A meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

CVCharan Thej Reddy VegivintiSPSivaguha Yadunath PrabhakaranAMA. W. McMillen

Discussion

Loading...

Member takes

Overview

Meta-analysis shows moderate efficacy of CAR-T cell therapy in CLL with 60.8% overall response rate, indicating clinical trials may improve future treatments.

Key Points

  • This meta-analysis aims to evaluate the efficacy of CAR-T cell therapies in Chronic Lymphocytic Leukemia (CLL).
  • Conducted a systematic literature search to identify clinical trials of CAR-T cell therapies for CLL.
  • Screened 408 records, including 4 clinical trials and 2 ASH abstracts for final analysis.
  • Used random-effect models to report primary outcomes including overall response rate, complete response, and minimal residual disease negativity.
  • Pooled overall response rate (ORR) of 60.8% with moderate heterogeneity among studies.
  • Complete response rate of 28.8% and minimal residual disease negativity of 70.8%.
  • Median duration of response reported as 18.9 months, with median progression-free survival and overall survival at 11.9 and 43.2 months respectively.

Cite This Study

Vegivinti et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0c8https://doi.org/10.1182/blood-2025-2740
View Full Paper
Ask AI
Bookmark
Share